Liquidia Technologies is trading 6.1% down at $73.22 as investors lock in profits following a strong run-up that left shares stretched versus analyst targets and valuation models.
- The stock is facing pressure alongside a broader sell-off in biotech peers, despite no fresh company-specific negative news emerging today.
- Internal models currently flag the company as materially overvalued after its recent significant price appreciation.